US FDA approves Verrica's skin disease treatment (updated)

Verrica Pharmaceuticals

21/07/2023 21:47

(Adds details and background in paragraphs 2 to 5)
       July 21 (Reuters) - The U.S. Food and Drug
Administration has approved Verrica Pharmaceuticals Inc's
 VRCA.O  treatment of a viral skin disease in adults and
children aged 2 years and above, the company said on Friday.
    The green light for Verrica's drug, Ycanth, makes it the
first approved treatment in the United States for viral skin
disease molluscum contagiosum.
    The FDA decision is a major milestone for the company after
it previously failed to secure a marketing approval for the drug
and device combination.
    The drug is delivered through a single-use applicator,
allowing for precise topical dosing and targeted administration.
    Verrica said it is preparing for commercial launch and to 
make Ycanth accessible by September 2023.
    The company did not immediately respond to a Reuters request
for pricing details. Needham analyst Serge Belanger estimated
the price would be around $500 an applicator, ahead of the
approval.

 (Reporting by Khushi Mandowara and Sriparna Roy in Bengaluru;
Editing by Shailesh Kuber)
 ((Sriparna.Roy@thomsonreuters.com;))